Antiproliferative effects of melatonin and CGP 52608

M Karasek1, M Pawlikowski

  • 1Laboratory of Electron Microscopy, Chair of Pathomorphology, Medical University of Lodz, Lodz, Poland. Micha.7497401@pharmanet.com.pl

Insights

Melatonin and CGP 52608 show similar antiproliferative effects on various cancer cells. Their mechanisms may be distinct, despite melatonin

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Melatonin is a hormone with potential anticancer properties.
  • RZR/ROR receptors are nuclear receptors implicated in various cellular processes.
  • CGP 52608 is an exogenous ligand for RZR/ROR receptors.

Purpose of the Study:

  • To compare the antiproliferative effects of melatonin and CGP 52608.
  • To investigate the potential involvement of RZR/ROR receptors in melatonin's action.

Main Methods:

  • In vitro antiproliferation assays.
  • Testing on mouse colonic adenocarcinoma, DU 145 human prostate cancer, MCF-7 human breast carcinoma, and rat diethylstilbestrol-induced prolactinoma cell lines.

Main Results:

  • Both melatonin and CGP 52608 demonstrated similar inhibitory effects on cancer cell proliferation.
  • The antiproliferative effects were observed across multiple cancer types.

Conclusions:

  • Melatonin and CGP 52608 exhibit comparable antiproliferative activities against neoplastic cells.
  • The precise mechanisms underlying these effects, and their potential relation to RZR/ROR receptors, require further investigation.